SCHEMBL2932360

SCHEMBL2932360

O=C(c1ccc(-c2cncc(-c3ccc(O)cc3)n2)cc1)N1CCOCC1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 2/20 0.60
MKNK2 Q9HBH9 2/20 0.60
HPGD P15428 5/20 0.57
SMN1; SMN2 Q16637 1/20 0.53
PHGDH O43175 1/20 0.51
ALDH1A1 P00352 1/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
KCNH2 Q12809 1/20 0.51
HDAC4 P56524 1/20 0.50
ATR Q13535 1/20 0.50
AKR1C3 P42330 1/20 0.47
BRD9 Q9H8M2 1/20 0.47
ERN1 O75460 1/20 0.46
RIPK1 Q13546 1/20 0.46
CHEK1 O14757 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2931412 0.88 CHEK1 (0.62) MKNK1MKNK2HPGDSMN1; SMN2ALDH1A1
SCHEMBL2929014 0.86 PHGDH (0.57) MKNK1MKNK2HPGDSMN1; SMN2PHGDH
SCHEMBL2786906 0.84 HPGD (0.73) MKNK1MKNK2HPGDSMN1; SMN2PHGDH
SCHEMBL2928315 0.83 RAB9A (0.48) MKNK1MKNK2HPGDALDH1A1NPC1
SCHEMBL2199279 0.83 PHGDH (0.71) HPGDSMN1; SMN2PHGDHALDH1A1AKR1C3
SCHEMBL2933163 0.82 BRD9 (0.51) MKNK1MKNK2HPGDALDH1A1NPC1
SCHEMBL2933173 0.82 HPGD (0.50) MKNK1MKNK2HPGDSMN1; SMN2PHGDH
SCHEMBL2926839 0.82 HPGD (0.53) MKNK1MKNK2HPGDSMN1; SMN2PHGDH
SCHEMBL2932693 0.82 KCNH2 (0.71) MKNK1MKNK2HPGDKCNH2ATR
SCHEMBL2936901 0.81 FASN (0.53) HPGDSMN1; SMN2RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 MKNK1 75/4885MKNK2 39/4885HPGD 3066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.